Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery
NRG Oncology RTOG 0436 研究中的患者报告结局 (PRO):一项评估在未接受手术治疗的食管癌患者中,西妥昔单抗联合紫杉醇、顺铂和放疗疗效的 III 期临床试验。
期刊:Quality of Life Research
影响因子:2.7
doi:10.1007/s11136-024-03736-7
Kachnic, Lisa A; Winter, Kathryn; Suntharalingam, Mohan; Ilson, David; Konski, André; Lloyd, Shane; McAvoy, Sarah A; Lad, Thomas; Olowokure, Olugbenga Gbenga; Samson, Pamela; Gore, Elizabeth M; Meyer, Joshua E; Videtic, Gregory M M; Clump, David A; Raben, Adam; Kayaleh, Omar; Barker, Jerry Jr; Haddock, Michael G; Hopkins, Judith O; Bruner, Deborah W